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Abstract
Background & Aims—Radiofrequency ablation (RFA) is commonly used to treat Barrett's 
esophagus (BE). We assessed the incidence of esophageal adenocarcinoma (EAC) after RFA, 
predictors of EAC, and EAC-specific and all-cause mortality rates.
Methods—We assessed outcomes in a multicenter study of RFA for BE. Kaplan-Meier curves of 
EAC incidence were stratified by baseline histology. Crude EAC incidence and mortality (both 
all-cause and EAC-specific) rates were calculated, and adjusted all-cause mortality rates were 
assessed. Logistic regression models were constructed to assess predictors of EAC and all-cause 
mortality.
Results—Among 4982 patients, 100 (2%) developed EAC (7.8/1000 person-years (PY)), and 9 
(0.2%) died of EAC (0.7/1000 PY) in a mean 2.7 ± 1.6 years. The incidence of EAC in non-
dysplastic BE (NDBE) was 0.5/1000 PY. Overall, 157 (3%) patients died during follow-up (all-
cause mortality 11.2/1000 PY). On multivariate logistic regression, baseline BE length (OR 1.1 
per cm) and baseline histology (ORs of 5.8 and 50.3 for low grade dysplasia and high grade 
dysplasia (HGD) respectively) predicted EAC incidence. Among 9 EAC deaths, 6 (67%) had 
baseline HGD and 3 (33%) had baseline intramucosal EAC. The most common causes of death 
were cardiovascular (15%) and extra-esophageal cancers (15%). No deaths were associated with 
RFA.
Conclusion—In this multicenter registry of RFA for BE, death from EAC was rare. The 
incidence of EAC was markedly lower than natural history studies, with the greatest absolute 
benefit seen in HGD.
Keywords
Keywords: Barrett's esophagus; radiofrequency ablation; incidence; esophageal adenocarcinoma; 
mortality
Introduction
Barrett's esophagus (BE) is defined as esophageal metaplasia in which normal squamous 
epithelium is replaced by intestinal metaplasia (IM). BE is associated with an increased risk 
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of esophageal adenocarcinoma (EAC), a cancer with a rapidly increasing incidence over the 
last four decades.1-5 Radiofrequency ablation (RFA) is an endoscopic treatment shown to be 
safe and effective in inducing reversion to squamous epithelium.6
RFA is performed with the goal of preventing the development of EAC by eliminating 
intestinal metaplasia and dysplasia.7 Endoscopic treatment has been associated with 
decreased rates of progression to EAC in the setting of dysplasia.6,8-10 However, few studies 
have assessed the risk of development of EAC and the risk of death from EAC after RFA. 
Also, no study has had adequate power to assess the risk of EAC following RFA for non-
dysplastic BE (NDBE). All cause-mortality in untreated BE may be increased, but due to 
non-neoplastic events, compared to the general population.11-17 However, little is known 
about all-cause mortality in patients after endoscopic treatment for BE.
The aims of this study were 1) to assess the incidence of EAC in patients with varying 
grades of dysplasia treated with RFA in a large multicenter sample, 2) to assess the mortality 
from EAC in patients receiving RFA, 3) to identify the predictors of EAC incidence in 
patients receiving RFA, and 4) to evaluate all-cause mortality in patients undergoing RFA.
Methods
U.S. RFA Patient Registry
The U.S. RFA Patient Registry is a multi-center study reporting processes and outcomes of 
care after treatment with RFA for BE at 148 institutions (113 community-based, 35 
academic-affiliated). The registry was developed as a research tool to assess clinical 
outcomes after RFA using the HALO Ablation Systems (Covidien, GI Solutions, Sunnyvale, 
CA), and was funded by Covidien. The registry did not mandate protocols for care, but 
provided a suggested protocol for treatment and follow-up of patients with BE. All 
physicians (n=320) used either Western institutional review board (IRB) approval, or 
obtained IRB approval through their respective institutions.
Registry Patient Eligibility
Patients were enrolled from July, 2007 to July, 2011, and followed intil July, 2014. Patients 
were eligible for inclusion if: (1) they had endoscopic evidence of columnar metaplasia in 
the tubular esophagus with accompanying biopsies from the esophagus demonstrating 
intestinal metaplasia, and (2) received circumferential and/or focal RFA treatment for BE. 
Subjects were classified using standardized histological grading, including non-dysplastic 
BE (NDBE), indefinite for dysplasia (IND), low-grade dysplasia (LGD), high-grade 
dysplasia (HGD), or esophageal adenocarcinoma (EAC), subclassified as intramucosal 
carcinoma (IMC), and invasive esophageal adenocarcinoma .18,19 Patients who had received 
one or more RFA treatments prior to enrollment had collection of retrospective data, with 
subsequent prospective collection for ensuing treatments. Patients who had not yet 
undergone treatment were prospectively enrolled in the study.
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Data Collection and Record Retention
Information collected in the registry included demographic data, baseline histology, 
endoscopic findings, number of treatment sessions, ablation outcomes, and complications. 
Data on mortality were prospectively collected, with cause of death reported by the enrolling 
center. All data were recorded on standardized case report forms. Data were collated into a 
central electronic database, with real-time monitoring for logic checks and consistency. Data 
were analyzed by investigators in the clinical epidemiology program at UNC (T32 
DK07634), who had complete access to the data.
Treatment Protocol
We provided a suggested treatment protocol to physician investigators, as previously 
described.20 This standardized protocol included medical therapy with twice-daily PPIs to 
minimize any baseline inflammatory changes of the mucosa and decrease acid reflux prior to 
and throughout RFA treatment, unless there was a documented history of antireflux surgery. 
Recommended treatment was based on previously published data,6 and called for a follow-
up endoscopy 2-3 months after initial RFA. At this endoscopy, additional circumferential or 
focal RFA treatment was performed for any visible residual columnar epithelium in the 
tubular esophagus, depending on the extent of the disease. If no visible columnar epithelium 
was observed, four-quadrant biopsies every cm were recommended throughout the length of 
the pre-treatment BE. If these biopsies were clear of BE on pathologic review, the patients 
entered the surveillance phase. Initial surveillance was recommended at 3 months for HGD 
or 6 months for NDBE, IND, or LGD. If follow-up biopsies revealed IM, dysplasia, or 
intramucosal EAC, recurrent treatment with RFA was recommended, unless mucosal 
nodularity was detected, in which case endoscopic mucosal resection was suggested. For 
invasive EAC, patients without contraindication were referred for consideration for 
esophagectomy or multimodality therapy as appropriate.
Adverse events were reported using standardized forms and terminology. Each site also 
complied with reporting guidelines for their institution regarding reporting adverse events to 
their IRB and FDA under the MDR reporting regulation in 21 C.F.R. Part 803.
Statistical Analysis
Statistical analysis was performed using Stata version 12.0 and SAS version 9.3. All patients 
completing at least one biopsy session after study enrollment were included. Additionally, in 
order to generate the most conservative estimates of mortality, any patient dying after the 
initial treatment but prior to the first biopsy session was also included in mortality 
calculations. There were no further exclusion criteria. For all-cause mortality and EAC-
specific mortality calculations, person-years (PY) were calculated as the difference between 
the date of the first RFA and the date of the last visit or death, whichever came first. For the 
EAC incidence calculation, the population was limited to patients who were EAC-free at 
baseline, had not undergone esophagectomy prior to study enrollment, and completed at 
least one biopsy session after enrollment. To provide the most conservative estimate of EAC 
incidence following RFA, for our primary analysis, any EAC detected at any time after the 
initial RFA treatment session was considered incident EAC. To assess the possible effect of 
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miscategorization of prevalent EAC as incident EAC, we also provide an estimate excluding 
the first year after RFA.
Bivariate analyses were performed with chi-square testing for categorical variables. For 
continuous variables with non-normal distributions, the Wilcoxon two-tailed t 
approximation (rank-sum) was used. Comparison of rates in the present study to historical 
controls was performed assuming Wald confidence limits and degrees of freedom of one 
less than the N for the smaller study or subgroup. Logistic regression models were 
constructed by including all variables significant at the p<0.2 level on bivariate testing and 
then reducing until all factors were significant at the p<0.05 level. Main effects multivariate 
odds ratios (ORs) were generated from the reduced model, and adjusted multivariate odds 
ratios were generated by adding known clinical predictors of EAC to the model. Kaplan-
Meier curves were generated by baseline histology. Crude incidence and mortality (all-cause 
and EAC-specific) rates were calculated, and age- and sex-adjusted all-cause mortality rates 
were calculated using the 2010 US population aged ≥45 years as reference.21 For odds ratios 
with empty strata and incidence rates of zero exact methods were applied.
Results
Of 5521 patients who enrolled in the U.S. RFA Patient Registry, 4982 (90%) met inclusion 
criteria. The remaining 539 (10%) did not undergo a biopsy session following initial 
treatment, and therefore were not at risk for a cancer diagnosis. These subjects were 
excluded from the risk analysis. The subjects were predominantly white (95%), male (74%), 
and had a mean age of 62 years (Table 1). At presentation, the mean BE segment was 4.1 
cm, and 2346 (47%) patients had NDBE, 368 (7%) had IND, 1020 (20%) had LGD, 990 
(20%) had HGD, 195 (4%) had intramucosal EAC, and 63 (1%) had invasive EAC. 
Compared to the subjects undergoing at least one biopsy session, those who were unbiopsied 
and therefore excluded were younger (mean 60 years vs 62 years, p<0.0001), and more 
likely to be non-white (8% vs 5%, p=0.0006) and female (30% vs 26%, p=0.03). These 
unbiopsied patients also had BE of lower histologic grade at baseline (61% NDBE vs 47%, 
p<0.0001).
The average time in study was 2.7 ± 1.6 years, producing a total of 13,835 PY of follow up, 
and patients underwent a mean of 2.9 ± 1.8 RFA treatments. Eighty-four percent of patients 
achieved complete eradication of intestinal metaplasia (CEIM). During the study period, 100 
(2%) incident cases of EAC developed and 9 (0.2%) patients died from EAC, among 157 
(3%) total deaths.
EAC Incidence
Among 4,982 patients in the study, 4,698 (94%) were included in the EAC incidence 
calculation. Over 12,804 PY, 100 (2%) patients developed EAC, an incidence rate of 7.8 per 
1000 PY (Table 2). Excluding the first year after RFA, 54 patients (1%) developed EAC 
over 8,924 PY, an incidence rate of 6.1 per 1,000 PY. Among all registry participants, the 
majority of incident EAC (n=83) occurred in patients with HGD (30.3 per 1000 PY) while 
an additional 12 occurred in patients with LGD (4.3 per 1000 PY), 2 occurred in patients 
with IND (2.1 per 1000 PY), and the remaining 3 cases occurred in patients with NDBE (0.5 
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per 1000 PY) (Figure 1). All three patients with NDBE who progressed to cancer had long 
segment disease (7, 10, and 11cm). The cancer incidence among NDBE with long segment 
disease (> 3 cm) was 1.5 per 1,000 person-years (95% CI 0.4-3.8) compared to 0.0 per 1,000 
person-years (95% CI 0.0-0.9) for short segment.
Of the 100 incident cases of EAC, 46 were invasive and 54 were IMC. Among the invasive 
cancers, 39 (85%) occurred in patients who never achieved CEIM while the remaining 7 
(15%) occurred after CEIM. Of 54 IMC, 24 (44%) never reached CEIM. An additional 16 
(30%) developed EAC, but were successfully treated to CEIM. The remaining 14 (26%) 
developed IMC after CEIM. Of those 14, 11 (79%) were treated back to CEIM. Thus, 27 
(50%) of the patients developing IMC concluded treatment with CEIM. Thirty-five patients 
with incident cancer underwent esophagectomy (21 invasive EAC, 14 IMC).
Compared to patients who did not develop EAC, patients with incident EAC were older 
(mean 66 years vs 61, p<0.0001) and more likely to be male (82% vs 73, p = 0.04) (Table 
1). They had longer BE segments at presentation (7 cm vs 4, p<0.0001), and higher 
pathologic grade (3% NDBE at presentation vs 51%, p<0.0001). Patients who developed 
EAC were more likely to have undergone gastric bypass prior to study enrollment (3% vs 
0.4%, p<0.0001). EAC incidence was not impacted by treatment in an academic vs a 
community center (13.9 per 1,000 person-years vs 5.7 per 1,000 person-years, RR adjusted 
for baseline histologic grade 0.92 [95% CI 0.62-1.38]).
Subsquamous BE was identified in a small number of patients (n = 136, 3%), but those 
patients more frequently went on to develop cancer (49.6 per 1,000 person-years vs. 7.1 per 
1,000 person-year, p < 0.0001; univariate OR 6.0 [95% CI 3.3-10.8]). The majority of 
subsquamous pathology was NDBE (n=94, 69%), while IND occurred in 3 (2%) patients, 
LGD in 14 (10%) and HGD in 19 (14%). Six cases of subsquamous adenocarcinomas were 
identified, 4 intramucosal cancers (3%) and 2 invasive cancers (1.5%). All subsquamous 
EAC occurred prior to CEIM. Following CEIM, subsquamous pathology was much less 
common, found in 31 of 3983 (0.8%) patients. There were 26 visits with subsquamous 
NDBE, 3 with indefinite for dysplasia, 3 with LGD, 6 with HGD and no cases of EAC.
Increasing BE length also appeared to be associated with EAC incidence. Among patients 
with LGD, incidence rates of cancer were higher among long (>3cm) segment BE (6.3 per 
1000 PY, 95% CI 2.4 - 10.2) than short segment (1.6 per 1000 PY, 95% CI 0.0 - 3.9). 
Among patients with HGD, incidence rates of cancer were also higher among long segment 
BE (37.9 per 1000 PY, 95% CI 28.6 - 47.1) than short segment BE (18.2 per 1000 PY, 95% 
CI 10.0 - 26.4).
On multivariate logistic regression, BE length, baseline histologic grade, and development 
of subsquamous pathology at any time during the study were associated with development 
of EAC. After adjustment for age, race, gender, and time in the study, each 1 cm increase in 
the length of the BE carried an OR of EAC development of 1.2 (95% CI 1.1-1.2) (Table 3). 
The odds of developing EAC increased with increasing histologic grade, with an adjusted 
OR of 3.6 for IND (95% CI 0.6-21.7), 5.9 for LGD (95% CI 1.6-21.5), and 48.44 for HGD 
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(95% CI 14.9-157.0) (Figure 2). Subsquamous pathology increased the odds of developing 
EAC (OR 2.7 95% CI [1.4-5.3]) as did prior gastric bypass (OR 9.4, 95% CI [1.1-78.7]).
A separate logistic regression model for invasive EAC again resulted in the same three 
factors—BE segment length, histologic grade, and subsquamous pathology at any time 
during the study—as the only significant factors predicting invasive EAC. Each 1 cm 
increase in the length of the BE segment carried an OR of EAC development of 1.1 (95% CI 
1.02-1.2). The OR for invasive EAC among patients with subsquamous pathology at any 
time was 2.6 (95% CI 1.02-6.4). The OR for IND was 2.8 (95% CI 0.3-31.2), for LGD it 
was 2.7 (0.5-16.6), and for HGD it was 32.5 (95% CI 7.5-140.7) (Table 3).
Comparison of EAC Risk to Historical Controls
The cancer incidence for each grade of dysplasia among treated patients in the registry was 
lower than that reported in past natural history studies. Historical incidence rates are 
reported in Supplemental table 1, along with significance testing against currently reported 
EAC incidence rates. Rates in treatment-naïve populations without dysplasia range from 1.0 
to 5.0 per 1000 PY compared to our rate of 0.5 per 1000 PY.22-24 In treatment-naïve 
populations with LGD the rates of progression range from 5.1 to 9.2 per 1000 PY compared 
to our rate of 4.3 per 1000 PY.23-25 A meta-analysis of treatment-naïve patients with HGD 
estimated the rate of progression to adenocarcinoma at 65.8 per 1000 PY compared to our 
rate of 30.3 per 1000 PY.2
EAC Mortality
Of 4,982 patients, 9 (0.2%) died from EAC over 13,835 PY, a rate of 0.7 per 1000 PY 
(Table 2). Six (67%) of the deaths occurred in patients who had HGD at baseline, a rate of 2 
per 1000 PY. The remaining 3 (33%) cases occurred in patients who presented with 
intramucosal EAC, a rate of 5.4 per 1000 PY. Compared to patients who did not die of EAC, 
those who died were older (mean 74 years vs 62, p=0.004) and had higher grade pathology 
at baseline (0% NDBE vs 47%, p<0.0001) (Table 1). EAC mortality was not impacted by 
treatment in a community vs. academic setting.
All-Cause Mortality
Of 4,982 patients, 157 (3%) died over 13,835 PY of follow up, an age- and sex-adjusted21 
rate of 11.7 per 1000 PY (Table 2). The mortality rate ratio for patients undergoing RFA for 
BE is 0.62 [95% CI 0.52-0.74]. Compared to those who did not die, those who died were 
older (mean 72 years vs 61, p<0.0001), had longer BE segments at baseline (mean 4.7cm vs 
4.1, p=0.01), and had higher pathologic grade at baseline (23% NDBE vs 48%, p<0.0001) 
(Table 1). Survival correlated with baseline histologic grade, with patients with NDBE least 
likely to die and patients with invasive EAC most likely to die (Figure 3). The adjusted 
mortality rate was 6.4 per 1000 PY for patients entering the registry with NDBE, 10.6 for 
IND, 6.8 for LGD, 24.8 for HGD, 27.1 for intramucosal EAC and 43.3 for invasive. The 
most common causes of death were cardiac (n=24, 15%), non-EAC cancers (n=24, 15%), 
and natural causes (n=21, 13%) (Table 4). EAC was the 5th leading cause of death (n=9, 
6%). There were no deaths related to RFA.
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A logistic regression model was constructed to evaluate factors associated with mortality. 
On multivariate analysis after adjustment for race, gender, and time in study, the odds of 
dying during the study increased with increasing age (OR 1.1 per year, 95% CI [1.1-1.1]), 
and with increasing histologic grade (OR for IND 1.6 [0.8-3.3], LGD 1.3 [0.7-2.2], HGD 2.7 
[1.7-4.4], intramucosal EAC 2.1 [1.0-4.6], and invasive EAC 12.0 [5.4-26.7]). Achieving 
CEIM was protective with an OR of 0.4 [0.3-0.6] (Table 3).
Discussion
Though the relationship of BE and EAC is well established, the impact of endoscopic 
therapy for BE on EAC incidence and mortality is not well described. Given that these 
therapies are performed in an effort to decrease death from cancer, such data are vital. The 
U.S. RFA Registry was designed to assess rates of EAC incidence and EAC-specific and 
overall death in a large, primarily community practice-based cohort. In this largest reported 
cohort of patients treated with RFA for BE, the rate of cancer incidence was low (7.8 per 
1000 PY). For each baseline grade of dysplasia, cancer incidence was markedly decreased 
compared to natural history estimates from previous studies. This suggests that endoscopic 
therapy of BE, when applied outside tertiary care centers and randomized controlled trials, is 
associated with a low rate of EAC incidence.
Increasing BE segment length, subsquamous BE, and higher baseline pathologic grade were 
associated with an increased risk of EAC, with the greatest risk coming in the setting of 
baseline HGD. Subsquamous BE was uncommon, and no subsquamous cancers occurred 
after CEIM. In this large cohort, we did not find evidence of the occurrence of de novo 
subsquamous cancer, since any patient with a biopsy containing submucosal cancer also had 
residual visible columnar tissue. Interestingly, however, the finding of subsquamous BE 
prior to CEIM was a strong risk factor for subsequent incident EAC. Whether this finding 
marks a group with a more aggressive disease state, is a chance finding due to the relatively 
low numbers of subsquamous BE patients who later developed EAC, or is due to another 
explanation, is unclear. During almost 14,000 PY of follow up, 9 patients died from EAC, a 
rate of 0.7 per 1000 PY. Among 157 total deaths, EAC tied for fifth behind causes typically 
associated with the 6th and 7th decades of life in the US population: cardiovascular disease, 
malignancy at sites outside the esophagus, “natural causes,” and multi-organ system failure.
This work is the first to provide a robust estimate of EAC incidence after endoscopic 
treatment for NDBE. It joins a small body of literature addressing the risk of development of 
EAC after RFA, though no prior research for this purpose has been composed primarily of 
patients treated outside of tertiary centers. Compared to results from a previous meta-
analysis evaluating the natural history of BE, RFA reduced the incidence of EAC from 6 per 
1000 PY to 0.5 per 1000 PY in NDBE, from 17 per 1000 PY to 4 per 1000 PY for LGD, and 
from 66 per 1000 PY to 30 per 1000 PY in HGD.26 Even when compared to the lowest 
estimates of risk available in NDBE, the currently reported risk is less than half, suggesting 
a protective effect.24 While care must be taken when comparing the current results to those 
from meta-analyses and previous cohort data due to the potential for heterogeniety of the 
compared patients and the possibility of a “healthy patient effect” in those treated with RFA, 
given the present data and past studies, RFA appears effective for reducing the incidence of 
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EAC after BE, regardless of histologic grade. The greatest benefit, in terms of absolute risk 
reduction compared to historical estimates, was seen in patients with HGD.
Unlike some previous analyses, which have assessed rates of progression and EAC after the 
achievement of CEIM,27 the present analysis assessed EAC risk after the first treatment with 
RFA. Requiring successful RFA prior to inclusion in this analysis would have excluded 63 
of the 100 incident cancers we report, as those cancers occurred in patients who never 
reached CEIM. However, the clinically relevant question to the patient considering RFA 
therapy is the cancer risk after initiation of therapy, not the risk after achieving CEIM. In 
calling any EAC occurring after initiation of therapy an incident EAC, we have likely 
miscategorized a proportion of prevalent EAC as incident EAC and consequently inflated 
our risk estimates by some degree. In order to avoid this miscategorization, some previous 
natural history studies have excluded EAC occurring within the first 6-12 months from 
calculations of cancer incidence.28 Such an approach would have decreased the EAC rates 
we report. However, we sought to generate the most conservative estimate of EAC risk we 
could, and the appropriate period of time necessary to exclude a cancer as prevalent is 
unknown.
Our findings that BE segment length and higher baseline pathologic grade increase the risk 
of EAC are corraborated by previous studies.24,26 To date, only baseline pathologic grade 
has been used in the determination of surveillance intervals after RFA. These data may be 
useful in further tailoring endoscopic surveillance following RFA to patient risk for EAC.
Previous studies have examined the mortality rate in patients with BE with inconsistent 
results. Several population-based studies have shown an increase in mortality rates in people 
with BE compared to the general population11,13,15,29 while several other studies have 
shown that the overall mortality rate excluding esophageal and gastric cancers was 
comparable to the general population.12,30 Our findings demonstrate a significant decrease 
in all-cause mortality among patients undergoing RFA for BE. This is likely due to a 
“healthy patient effect,” analogous to the healthy worker effect, wherein the patients 
selected for RFA would have been selected in part for generally good health and an 
expectation that the procedure would be well tolerated. The all-cause mortality rate in our 
population was more than 15 times higher than the EAC mortality rate. Patients treated with 
RFA for their BE were far more likely to die from cardiac disease or cancer at sites outside 
the esophagus than from esophageal cancer, which is consistent with previous research.29,30
Interestingly, almost half of this study population had NDBE. This finding suggests that in 
real-world practice, treatment of NDBE with RFA is common. Societal guidelines are 
divided on this issue, with AGA guidelines suggesting that RFA should be an option in the 
treatment of select individuals with NDBE and for those with confirmed LGD, while the 
British Society of Gastroenterology (BSG) stands against the use of ablative therapy in those 
with LGD or NDBE.31-33 As the BSG guidelines note, recently available level one evidence 
regarding the efficacy of RFA in the treatment of LGD may impact future 
recommendations.10 As to the impact of a large number of NDBE patients in the present 
study, it might lead to under-estimation of cancer risk in the overall cohort compared to 
other RFA cohorts with larger proportions of dysplastic patients, but it would not impact the 
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rates when stratified by degree of baseline dysplasia. As we seek to better understand the 
role of ablative therapy in the BE disease spectrum, precise estimates of cancer risk 
following ablation of patients with varying degrees of histologic disease severity are 
essential to understand the value of the intervention. Currently, policy makers and decision 
analysts rely on expert opinion for these estimates. The current data allow a more evidence-
based approach to utilization decisions for ablation in BE.
Our study has several limitations that must be considered. Our data are derived from an 
observational study where care paradigms including surveillance and biopsy intervals were 
recommended but not mandated. Given the size of this study, local pathology labs were used 
for the assessment of histology. While this is consistent with care of BE patients in the U.S., 
it likely introduces a higher degree of misclassification than would a single expert 
pathologist. Additionally, when comparing our data to historical estimates of cancer risk, 
there may be selection bias toward a healthier patient population in the present study since 
patients were only included if they were healthy enough to tolerate RFA treatment sessions. 
Due to this potential for selection bias, we suggest caution in the interpretation of the 
comparisons between these data and incidence rates from natural history studies. Also, 
approximately 10% of our patients did not undergo at least one biopsy session, and therefore 
were not included in our analyses. These patients tended to be younger with lower grade 
disease at baseline, making it less likely that differential progression in these patients would 
increase our estimates of EAC risk or death. However, we cannot exclude the possibility that 
patients who did not complete at least one biopsy session could have experienced EAC at a 
rate higher than the remainder of the cohort. Finally, our study suffers from the limitations 
which hamper any research evaluating cause of death: presumed causes of death are 
demonstrably inconsistent with autopsy findings,34 and, while most Americans do not 
undergo autopsy, the lack of autopsy data may under- or over-estimate specific causes. 
While the lack of post-mortem results increases the possibility that EAC mortality could be 
underestimated, given the frequent endoscopies in this cohort and their known diagnosis of 
BE, we suspect that the rate of undiagnosed EAC leading to mortality would be low.
There are several important strengths to this study. First, we report the largest cohort of 
patients treated with RFA for BE. Additionally, our study utilized 320 physician participants 
from 148 community-based and academic-affiliated institutions. The diversity of practice 
settings and variety of procedural volumes improves the generalizability of our results. All 
study definitions were a priori, and data were collected in a standardized fashion. We 
applied the most conservative possible conventions to assessing cancer and mortality rates.
In conclusion, after initiating treatment with RFA, the risk of incident EAC or death from 
EAC is small. EAC incidence rates are lower than estimates derived from natural history 
studies when stratified by baseline histology, including a 3 to 10-fold decrease in the rate of 
progression from NDBE to EAC and an at least 50% decrease in the rate of HGD to EAC. 
However, comparisons between these estimates and historical controls are susceptible to 
selection bias. We have also found the risk of death to be similar in patients treated with 
RFA compared to the broader US population. Baseline histologic grade is the most 
important predictor not only of cancer development, but also of death from cancer and from 
non-cancer causes. EAC accounts for only a small portion of deaths in patients with BE, in 
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both treated cohorts as well as in past reports of untreated cohorts. The leading causes of 
death of BE patients are heart disease and cancers outside the esophagus.
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Refer to Web version on PubMed Central for supplementary material.
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BE Barrett's esophagus
CEIM complete eradication of intestinal metaplasia
CI confidence interval
EMR endoscopic mucosal resection
EAC esophageal adenocarcinoma
HGD high grade dysplasia
IND indefinite for dysplasia
LGD low grade dysplasia
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Figure 1. Kaplan-Meier Curves of EAC Incidence by Baseline Pathology
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Figure 2. Probability of Developing EAC Based on Baseline Pathology and BE Segment Length. 
Derived via Multivariate Logistic Regression
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Figure 3. Kaplan-Meier Survival Curves by Baseline Histology
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Table 3
Multivariate Logistic Regression Results for Predictors of EAC and Mortality
Multivariate Main Effect Odds Ratio [95% CI] Adjusted‡ Multivariate Odds Ratio [95% CI]
Predictors of Incident EAC
BE Length (per cm) 1.1 [1.1, 1.2] 1.2 [1.1, 1.2]
Subsquamous BE 2.9 [1.5, 5.4] 2.7 [1.4, 5.2]
Histology (reference = NDBE)
 IND 3.6 [0.6, 21.7] 3.6 [0.6, 21.7]
 LGD 7.4 [2.1, 26.3] 5.9 [1.6, 21.5]
 HGD 51.8 [16.2, 165.2] 48.4 [14.9, 157.0]
Predictors of Invasive EAC
BE Length (per cm) 1.1 [1.01, 1.2] 1.1 [1.02, 1.2]
Subsquamous BE 3.0 [1.3, 7.1] 2.6 [1.02, 6.4]
Histology (reference = NDBE)
 IND 2.8 [0.3, 31.6] 2.8 [0.3, 31.2]
 LGD 4.9 [1.0, 25.6] 2.7 [0.5, 16.6]
 HGD 36.5 [8.7, 153.4] 32.5 [7.5, 140.7]
Predictors of All-Cause Mortality
Age (per year) 1.1 [1.1, 1.1] 1.1 [1.1, 1.1]
Achieved CEIM 0.2 [0.1, 0.3] 0.4 [0.3, 0.6]
Histology (reference = NDBE)
 IND 1.5 [0.7, 3.0] 1.6 [0.8, 3.3]
 LGD 1.1 [0.6, 1.9] 1.3 [0.7, 2.2]
 HGD 2.2 [1.4, 3.4] 2.7 [1.7, 4.4]
 Intramucosal EAC 1.6 [0.8, 3.4] 2.1 [1.0, 4.6]
 Invasive EAC 8.6 [4.1, 18.2] 12.0 [5.4, 26.7]
‡
Predictors of EAC model adjusted for age, race, gender, and time in study. Predictors of all-cause mortality model adjusted for race, gender, and 
time in study.
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